German group Merck to buy Bio-Techne in $11.3bn deal - Financial Times
Financial Times
F
Financial Times
Original Source
German pharmaceutical group Merck is acquiring US-based Bio-Techne in an $11.3 billion deal, marking its largest acquisition in over a decade. The acquisition aligns with Merck's strategy to become a leading supplier of tools used in drug discovery, diagnostics, and biopharmaceutical manufacturing.
German group Merck to buy Bio-Techne in $11.3bn deal
More context. More depth. More why
Our journalists help you see the whole story.
More context. More depth. More why
Our journalists help you see the whole story.
Try the FT for just £1
* Sign In * Subscribe
Open side navigation menuOpen search bar
SubscribeSign In
Popular Searches
* What is the latest news on the UK economy? * Western support for Ukraine * How will AI be regulated? * UK inflation vs the world * How will the UK economy fare in 2026?
* Home * World Sections
+ World Home + Middle East war + Global Economy + UK + US + China + Africa + Asia Pacific + Emerging Markets + Europe + War in Ukraine + Americas + Middle East & North Africa Most Read
+ SpaceX bond sale signals markets are in ‘bubble territory’, warns Allianz CIO + Dimon promotes two potential successors at JPMorgan + Unions combine to try to stop Ed Miliband becoming chancellor + Rome airports warn of summer ‘disaster’ unless EU border controls suspended + UAE billionaire’s son revealed as buyer of £190mn London mansion * US Sections
+ US Home + US Economy + US Companies + US Politics & Policy Most Read
+ SpaceX bond sale signals markets are in ‘bubble territory’, warns Allianz CIO + Dimon promotes two potential successors at JPMorgan + Trump demands ‘loyalty’ from Nato allies and slams lack of support in Iran war + Oil price back at prewar levels as Gulf flows pick up + Trump says Burnham ‘extremely liberal’ * Companies Sections
+ Companies Home + Energy + Financials + Health + Industrials + Media + Professional Services + Retail & Consumer + Tech Sector + Telecoms + Transport Most Read
+ SpaceX bond sale signals markets are in ‘bubble territory’, warns Allianz CIO + Dimon promotes two potential successors at JPMorgan + Rome airports warn of summer ‘disaster’ unless EU border controls suspended + UAE billionaire’s son revealed as buyer of £190mn London mansion + Oil price back at prewar levels as Gulf flows pick up * Tech Sections
+ Tech Home + Artificial intelligence + Semiconductors + Cyber Security + Social Media Most Read
+ The reason China is building most of the world’s robots + Apple increases MacBook and iPad prices by 20% + Bitcoin hits 20-month low as market sentiment sours + Micron posts 15-fold profit surge in boost for global AI stocks + Micron shares jump as blockbuster results spark Wall Street tech shake-up * Markets Sections
+ Markets Home + Alphaville + Markets Data + Private markets + Equities + Bonds + Currencies + Commodities + Crypto + Monetary Policy Radar + Wealth Management + Moral Money + ETF Hub + Asset management Most Read
+ SpaceX bond sale signals markets are in ‘bubble territory’, warns Allianz CIO + Oil price back at prewar levels as Gulf flows pick up + Cathie Wood’s bet on football group turned crypto hoarder backfires + Bitcoin hits 20-month low as market sentiment sours + Flagship Ares private credit fund hit by 14% withdrawal requests * Climate * Opinion Sections
+ Opinion Home + Columnists + The FT View + The Big Read + Lex + Obituaries + Letters Most Read
+ Putin’s system is in a state of slow implosion + Andy Burnham’s Ed Miliband test + The future of TV: lots of choice, lots of hassle + The rise and fall of US hegemony + What if ideas aren’t getting harder to find, after all? * Lex * Stock Picking Game * Life & Arts Sections
+ Life & Arts Home + Arts + Books + Food & Drink + FT Magazine + House & Home + Style + Puzzles + Travel + FT Globetrotter Most Read
+ UAE billionaire’s son revealed as buyer of £190mn London mansion + The future of TV: lots of choice, lots of hassle + Why is getting to a World Cup game so hard? + Tate Modern’s Frida Kahlo is a blockbuster with a fatal flaw + Hot property: five homes for sale in Marrakech, Morocco * How To Spend It
MenuSearch
* Home * World * US * Companies * Tech * Markets * Climate * Opinion * Lex * Stock Picking Game * Life & Arts * How To Spend It
Financial Times
SubscribeSign In
Popular Searches
* What is the latest news on the UK economy? * Western support for Ukraine * How will AI be regulated? * UK inflation vs the world * How will the UK economy fare in 2026?
Pharmaceuticals sector
Manage your delivery channels here
German group Merck to buy Bio-Techne in $11.3bn deal
Acquisition of US medical tools maker will be life sciences company’s biggest in more than a decade
!Large blue Merck KGaA logo sculpture displayed on grass in front of a modern office building.
*The deal is part of Merck’s strategy to become a leading supplier of tools used in drug discovery, diagnostics and biopharmaceutical manufacturing
* German group Merck to buy Bio-Techne in $11.3bn deal on x (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on facebook (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on linkedin (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on whatsapp (opens in a new window) *
current progress 0%
* German group Merck to buy Bio-Techne in $11.3bn deal on x (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on facebook (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on linkedin (opens in a new window) * German group Merck to buy Bio-Techne in $11.3bn deal on whatsapp (opens in a new window) *
Florian Müller in Frankfurt
Published7 hours ago
Jump to comments section
Stay informed with free updates
Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox.
Need help?
🔗 Share Article
Tags:#ميرك الألمانية#بيو-تكن#استحواذ#11.3 مليار دولار#العلوم الحياتية#الصيدلة